Amyloid Beta Peptides Affect Pregnenolone and Pregnenolone Sulfate Levels in PC-12 and SH-SY5Y Cells Depending on Cholesterol

Neurochemical Research

Volumn 41, Issue 7, 2016, Pages 1700-1712

  Calan, Ozlem Gursoy ^a   Akan, Pinar ^a   Cataler, Aysenur ^a   Dogan, Cumhur ^a   Kocturk, Semra ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Amyloid beta toxicity; Cholesterol; Neuronal toxicity; Neurosteroid; Pregnenolone; Pregnenolone sulfate

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PREGNENOLONE; PREGNENOLONE SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHROMAFFIN CELL; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; NEUROBLASTOMA CELL LINE; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SH SY5Y CELL LINE; ANIMAL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL SURVIVAL; CHOLESTEROL; HUMANS; PC12 CELLS; PREGNENOLONE; RATS;

EID: 84961677890     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-016-1886-0     Document Type: Article

References (79)

1. World Alzheimer Report (2014) Dementia and risk reduction. 2014. http://www.alz.co.uk/research/world-report-2014
2. World Health Organization (Media centre) Dementia March 2015. http://www.who.int/mediacentre/factsheets/fs362/en/
3. Zhu X, Perry G, Smith MA, Wang X (2013) Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J Alzheimer’s Dis: JAD 33(Suppl 1):S253–S262
4. Nalivaeva NN, Turner AJ (2013) The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett 587(13):2046–2054
5. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer’s disease. Sub-cell Biochem 65:329–352
6. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL et al (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci USA 100(17):10032–10037
7. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356
8. Ling Y, Morgan K, Kalsheker N (2003) Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer’s disease. Int J Biochem Cell Biol 35(11):1505–1535
9. Przedborski S, Vila M, Jackson-Lewis V (2003) Neurodegeneration: what is it and where are we? J Clin Investig 111(1):3–10
10. Morley JE, Farr SA (2014) The role of amyloid-beta in the regulation of memory. Biochem Pharmacol 88(4):479–485
11. Finder VH, Glockshuber R (2007) Amyloid-beta aggregation. Neuro-degener Dis 4(1):13–27
12. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82(12):4245–4249
13. Cole SL, Vassar R (2007) The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener 2:22
14. Evin G, Weidemann A (2002) Biogenesis and metabolism of Alzheimer’s disease Abeta amyloid peptides. Peptides 23(7):1285–1297
15. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF et al (1994) Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 45(3):373–379
16. Wang R, Sweeney D, Gandy SE, Sisodia SS (1996) The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem 271(50):31894–31902
17. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250(4978):279–282
18. Lee SY, Lee JW, Lee H, Yoo HS, Yun YP, Oh KW et al (2005) Inhibitory effect of green tea extract on beta-amyloid-induced PC12 cell death by inhibition of the activation of NF-kappaB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Brain Res Mol Brain Res 140(1–2):45–54
19. Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, Gulyaeva NV (2003) Single intracerebroventricular administration of amyloid-beta (25–35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Res Bull 61(2):197–205
20. Stepanichev MY, Zdobnova IM, Zarubenko II, Moiseeva YV, Lazareva NA, Onufriev MV et al (2004) Amyloid-beta(25–35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiol Behav 80(5):647–655
21. Stepanichev MY, Onufriev MV, Yakovlev AA, Khrenov AI, Peregud DI, Vorontsova ON et al (2008) Amyloid-beta (25-35) increases activity of neuronal NO-synthase in rat brain. Neurochem Int 52(6):1114–1124
22. Li G, Ma R, Huang C, Tang Q, Fu Q, Liu H et al (2008) Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms. Neurosci Lett 442(2):143–147
23. Schaeffer V, Meyer L, Patte-Mensah C, Eckert A, Mensah-Nyagan AG (2008) Dose-dependent and sequence-sensitive effects of amyloid-beta peptide on neurosteroidogenesis in human neuroblastoma cells. Neurochem Int 52(6):948–955
24. Brown RC, Cascio C, Papadopoulos V (2000) Pathways of neurosteroid biosynthesis in cell lines from human brain: regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid peptide. J Neurochem 74(2):847–859
25. Pikuleva IA (2006) Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos 34(4):513–520
26. Stefani M, Liguri G (2009) Cholesterol in Alzheimer’s disease: unresolved questions. Curr Alzheimer Res 6(1):15–29
27. Vallee M, Purdy RH, Mayo W, Koob GF, Le Moal M (2003) Neuroactive steroids: new biomarkers of cognitive aging. J Steroid Biochem Mol Biol 85(2–5):329–335
28. Herson PS, Koerner IP, Hurn PD (2009) Sex, sex steroids, and brain injury. Semin Reprod Med 27(3):229–239
29. Mellon SH (2007) Neurosteroid regulation of central nervous system development. Pharmacol Ther 116(1):107–124
30. Baulieu EE, Robel P, Schumacher M (2001) Neurosteroids: beginning of the story. Int Rev Neurobiol 46:1–32
31. Guarneri P, Cascio C, Russo D, D’Agostino S, Drago G, Galizzi G et al (2003) Neurosteroids in the retina: neurodegenerative and neuroprotective agents in retinal degeneration. Ann N Y Acad Sci 1007:117–128
32. Marx CE, Jarskog LF, Lauder JM, Gilmore JH, Lieberman JA, Morrow AL (2000) Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res 871(1):104–112
33. Schaeffer V, Patte-Mensah C, Eckert A, Mensah-Nyagan AG (2008) Selective regulation of neurosteroid biosynthesis in human neuroblastoma cells under hydrogen peroxide-induced oxidative stress condition. Neuroscience 151(3):758–770
34. Charalampopoulos I, Remboutsika E, Margioris AN, Gravanis A (2008) Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab 19(8):300–307
35. Guarneri P, Russo D, Cascio C, De Leo G, Piccoli F, Guarneri R (1998) Induction of neurosteroid synthesis by NMDA receptors in isolated rat retina: a potential early event in excitotoxicity. Eur J Neurosci 10(5):1752–1763
36. Akan P, Kizildag S, Ormen M, Genc S, Oktem MA, Fadiloglu M (2009) Pregnenolone protects the PC-12 cell line against amyloid beta peptide toxicity but its sulfate ester does not. Chem Biol Interact 177(1):65–70
37. Gursoy E, Cardounel A, Kalimi M (2001) Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid beta protein toxicity. Neurochem Res 26(1):15–21
38. Cascio C, Guarneri R, Russo D, De Leo G, Guarneri M, Piccoli F et al (2002) A caspase-3-dependent pathway is predominantly activated by the excitotoxin pregnenolone sulfate and requires early and late cytochrome c release and cell-specific caspase-2 activation in the retinal cell death. J Neurochem 83(6):1358–1371
39. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR (2004) Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62(10):1869–1871
40. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer’s disease: the cholesterol connection. Nat Neurosci 6(4):345–351
41. Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Cunningham R et al (2014) Total cholesterol and neuropsychiatric symptoms in Alzheimer’s disease: the impact of total cholesterol level and gender. Dement Geriatr Cogn Disord 38(5–6):300–309
42. Reiman EM, Chen K, Langbaum JB, Lee W, Reschke C, Bandy D et al (2010) Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer’s disease and normal aging. NeuroImage 49(1):169–176
43. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 68(11):1385–1392
44. Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, Ghribi O (2009) Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol Neurodegener 4:1
45. Colell A, Fernandez A, Fernandez-Checa JC (2009) Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease. J Bioenerg Biomembr 41(5):417–423
46. Prasanthi RPJ, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O (2008) Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer’s disease. Mech Ageing Dev 129(11):649–655
47. Di Scala C, Chahinian H, Yahi N, Garmy N, Fantini J (2014) Interaction of Alzheimer’s beta-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. Biochemistry 53(28):4489–4502
48. Cossec JC, Marquer C, Panchal M, Lazar AN, Duyckaerts C, Potier MC (2010) Cholesterol changes in Alzheimer’s disease: methods of analysis and impact on the formation of enlarged endosomes. Biochim Biophys Acta 1801(8):839–845
49. Tillement JP, Lecanu L, Papadopoulos V (2010) Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options. Pharmacology 85(1):1–17
50. Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271(8):4436–4440
51. Guarneri P, Cascio C, Piccoli T, Piccoli F, Guarneri R (2000) Human neuroblastoma SH-SY5Y cell line: neurosteroid-producing cell line relying on cytoskeletal organization. J Neurosci Res 60(5):656–665
52. Mruthinti S, Capito N, Sood A, Buccafusc JJ (2007) Cytotoxicity of Abeta1-42, RAGE23-54, and an Abeta-RAGE complex in PC-12 cells. Curr Alzheimer Res 4(5):581–586
53. Schaeffer V, Patte-Mensah C, Eckert A, Mensah-Nyagan AG (2006) Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer’s disease key proteins. J Neurobiol 66(8):868–881
54. Zhou YQ, Yang ZL, Xu L, Li P, Hu YZ (2009) Akebia saponin D, a saponin component from Dipsacus asper Wall, protects PC 12 cells against amyloid-beta induced cytotoxicity. Cell Biol Int 33(10):1102–1110
55. Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K (2008) Targeted proteomics in Alzheimer’s disease: focus on amyloid-beta. Expert Rev Proteomics 5(2):225–237
56. Irie K, Murakami K, Masuda Y, Morimoto A, Ohigashi H, Ohashi R et al (2005) Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer’s disease. J Biosci Bioeng 99(5):437–447
57. Calan OG, Akan P, Bagriyanik HA, Fadiloglu M (2014) The assessment of vital responses of human and rat neuronal cells against to amyloid beta peptide and neuroactive steroid treatment. J Neurol Sci Turk 31(1):28–39
58. Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R et al (2002) Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22(5):1679–1689
59. Schumacher M, Liere P, Akwa Y, Rajkowski K, Griffiths W, Bodin K et al (2008) Pregnenolone sulfate in the brain: a controversial neurosteroid. Neurochem Int 52(4–5):522–540
60. Semeniuk T, Jhangri GS, Le Melledo JM (2001) Neuroactive steroid levels in patients with generalized anxiety disorder. J Neuropsychiatry Clin Neurosci 13(3):396–398
61. Fernandez A, Llacuna L, Fernandez-Checa JC, Colell A (2009) Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J Neurosci 29(20):6394–6405
62. Gamble W, Vaughan M, Kruth HS, Avigan J (1978) Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 19(8):1068–1070
63. Tagawa N, Nakata Y, Kusuda S, Kobayashi Y, Watanabe F (1997) Serum levels of 16-dehydropregnenolone sulfate during the early neonatal period. Biol Pharm Bull 20(1):76–78
64. Tagawa N, Tamanaka J, Fujinami A, Kobayashi Y, Takano T, Fukata S et al (2000) Serum dehydroepiandrosterone, dehydroepiandrosterone sulfate, and pregnenolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. Clin Chem 46(4):523–528
65. Beaujean D, Mensah-Nyagan AG, Do-Rego JL, Luu-The V, Pelletier G, Vaudry H (1999) Immunocytochemical localization and biological activity of hydroxysteroid sulfotransferase in the frog brain. J Neurochem 72(2):848–857
66. Shirakawa H, Katsuki H, Kume T, Kaneko S, Akaike A (2006) Aminoglutethimide prevents excitotoxic and ischemic injuries in cortical neurons. Br J Pharmacol 147(7):729–736
67. Zhu TS, Glaser M (2008) Regulatory role of cytochrome P450scc and pregnenolone in myelination by rat Schwann cells. Mol Cell Biochem 313(1–2):79–89
68. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–63
69. Lobner D (2000) Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis? J Neurosci Methods 96(2):147–152
70. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP (1998) Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31(1):1–9
71. Westerink RH, Ewing AG (2008) The PC12 cell as model for neurosecretion. Acta Physiol 192(2):273–285
72. Baulieu EE (1998) Neurosteroids: a novel function of the brain. Psychoneuroendocrinology. 23(8):963–987
73. Wang M (2011) Neurosteroids and GABA-a receptor function. Front Endocrinol 2:44
74. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A et al (2002) Neurosteroid quantification in human brain regions: comparison between Alzheimer’s and nondemented patients. J Clin Endocrinol Metab 87(11):5138–5143
75. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS et al (2000) Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4):321–331
76. Kohjitani A, Fuda H, Hanyu O, Strott CA (2008) Regulation of SULT2B1a (pregnenolone sulfotransferase) expression in rat C6 glioma cells: relevance of AMPA receptor-mediated NO signaling. Neurosci Lett 430(1):75–80
77. Plassart-Schiess E, Baulieu EE (2001) Neurosteroids: recent findings. Brain Res Brain Res Rev 37(1–3):133–140
78. Stoffel-Wagner B (2001) Neurosteroid metabolism in the human brain. Eur J Endocrinol 145(6):669–679
79. Guarneri P, Russo D, Cascio C, De Leo G, Piccoli T, Sciuto V et al (1998) Pregnenolone sulfate modulates NMDA receptors, inducing and potentiating acute excitotoxicity in isolated retina. J Neurosci Res 54(6):787–797